South Korean software provider Hyundai Mobis selected Israel's Cognata, a provider of simulation software and training data for driver-assistance systems and autonomous vehicles, to test its offerings.
Cognata noted that large-scale simulation provides the only environment where autonomous vehicle technology and advanced driver-assistance systems (ADAS) can be safely tested and validated.
The deal brings Cognata's technology to one of South Korea's largest automotive groups during an incredible momentum and growth in autonomous driving and ADAS in South Korea.
Lee Chang-ik, who manages autonomous vehicle simulation in Hyundai Mobis, said Cognata would accelerate their time-to-market offerings.
According to NH Investment & Securities analyst Cho Soo-hong, Hyundai Mobis should see mid to long-term earnings growth as a key automotive electronics provider for Hyundai Motor Group, set to introduce its E-GMP EV-dedicated platform in 2021.


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs 



